News
$Pieris Pharmaceuticals (PIRS.US)$ Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
3 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
Ongoing Phase 3 trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations, a program with FDA's Breakthrough Therapy Designation and Fast Track Designation
3 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
Ongoing Phase 3 trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations, a program with FDA's Breakthrough Therapy Designation and Fast Track Designation
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
